Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

NCT06832267 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)

Sponsor

Zhejiang Cancer Hospital